About this trial
This single-center randomized sibling-oocyte controlled trial evaluates whether co-culture with induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) improves rescue in vitro maturation (r-IVM) outcomes of surplus germinal vesicle (GV) oocytes collected during routine IVF treatment. Eligible GV oocytes from each enrolled participant are allocated within participant in a 1:1 ratio to either conventional r-IVM or r-IVM with OSC co-culture. The primary outcome is the metaphase II (MII) maturation rate after 24 hours of culture. Secondary outcomes include fertilization rate, day 3 embryo formation, good-quality day 3 embryo rate, blastocyst formation, and good-quality blastocyst rate. All embryos generated in the study are for research purposes only and will not be used for clinical embryo transfer.
Eligibility criteria
Qualifiers
Women aged 18 to 45 years.
At least 2 GV oocytes retrieved in a single oocyte retrieval cycle.
Voluntary informed consent from the couple to participate in the study.
Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.
Disqualifiers
Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE.
Use of donor gametes, including donor oocytes or donor sperm.
Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.
Trial design
Treatments tested in this trial
- Conventional rescue in vitro maturation
- Rescue in vitro maturation with iPSC-derived ovarian support cell co-culture
Treatment groups
Sponsors and collaborators
Hung Vuong Hospital
Lead sponsor
Dioseve Inc.
Collaborator